Atea Pharma Rg

Clinical‑stage biopharma Atea Pharma develops oral antiviral regimens for severe viral infections, with a Phase 3 HCV candidate combining bemnifosbuvir and ruzasvir, plus a Phase II‑C COVID therapy licensed to Roche. Headquartered in Boston.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 56
HQ: Boston

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
AVIR	Atea Pharma Rg Cap: 0.3B	EQUITY	NMS	USD	US04683R1068	Active	📈